Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density.
Sixty postmenopausal women were randomly assigned to three types of treatment with intranasal salmon calcitonin (SCT) plus calcium 500 mg daily (group A: 100 IU daily of SCT; group B: 100 IU daily of SCT for alternate cycles of 2 months with a 1-month interval; group C: 100 IU daily of SCT for alternate cycles of 3 months of treatment followed by a 3-month interval) or calcium 500 mg daily alone (control group). Lumbar density significantly decreased in the control group while it maintained the initial value in both continuously or cyclically treated groups. The bone density of the proximal and distal forearm in treated and control groups did not show significant changes after 12 months.
Perrone
G
G
Clinic of Obstetrics and Gynecology, University of Rome La Sapienza, Italy.
Galoppi
P
P
Valente
M
M
Capri
O
O
D'Ubaldo
C
C
Anelli
G
G
Zichella
L
L
D000281:Administration, Intranasal; D015519:Bone Density / Q000187:drug effects*; D002116:Calcitonin / Q000008:administration & dosage* / Q000494:pharmacology; D002118:Calcium / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae / Q000187:drug effects; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D013997:Time Factors
C028815:salmon calcitonin; D002116:Calcitonin; D002118:Calcium